Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of CKD-387 vs D484 (Metformin) in Healthy Adults
NCT03738449Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2019
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum plasma concentration of Metformin and Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration. Started Jan 2019; status: completed.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03738449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03738449.